Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Australia’s Therapeutic Goods Administration (TGA) approves Feraccru® to treat Iron Deficiency with or without anaemia in adults

9 Mar 2021

Shield Therapeutics plc, notes that Australia’s Therapeutics Goods Administration has registered Feraccru® in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anaemia in adults.

Feraccru® is already approved in the UK, European Union, Switzerland and United States for the treatment of iron deficiency with or without anaemia in adults. Norgine Pty Ltd will lead all marketing activities in Australia. 

The Therapeutic Goods Administration (TGA) is Australia’s regulatory authority for medicinal products (“therapeutic goods”).

Back to news